Cargando…

Comment on ‘Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome’

Detalles Bibliográficos
Autores principales:	Dell'Oglio, Paolo, Stabile, Armando, Gandaglia, Giorgio, Briganti, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294470/ https://www.ncbi.nlm.nih.gov/pubmed/27780195 http://dx.doi.org/10.1038/bjc.2016.346

Ejemplares similares

Reply to ‘Comment on “Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome”’
por: Berney, Daniel M
Publicado: (2017)

Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer
por: Gandaglia, Giorgio, et al.
Publicado: (2023)

Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes
por: Dell’Oglio, Paolo, et al.
Publicado: (2017)

Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer
por: Scuderi, Simone, et al.
Publicado: (2023)

Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome
por: Berney, Daniel M, et al.
Publicado: (2016)

Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes
por: Gandaglia, Giorgio, et al.
Publicado: (2022)

Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?—a narrative review
por: Pellegrino, Antony, et al.
Publicado: (2022)

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer
por: Bandini, Marco, et al.
Publicado: (2017)

Grade and stage misclassification in intermediate unfavorable‐risk prostate cancer radiotherapy candidates
por: Sorce, Gabriele, et al.
Publicado: (2022)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Highlighting the road towards new disease-specific comorbidity indices
por: Dell’Oglio, Paolo, et al.
Publicado: (2020)

Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians
por: Gasparrini, Silvia, et al.
Publicado: (2019)

Prostate Cancer in Renal Transplant Recipients: Results from a Large Contemporary Cohort
por: Marra, Giancarlo, et al.
Publicado: (2022)

Contemporary Grading of Prostate Cancer: The Impact of Grading Criteria and the Significance of the Amount of Intraductal Carcinoma
por: Tzelepi, Vasiliki, et al.
Publicado: (2021)

Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer
por: Sopyllo, Konrad, et al.
Publicado: (2021)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

Comment on ‘Hand pattern indicates risk of prostate cancer’
por: Cheema, M, et al.
Publicado: (2011)

Comments on the article “Biomarkers for prostate cancer” by Eric Schiffer
por: Marshall, Sumner
Publicado: (2009)

Contemporary Management of Prostate Cancer
por: Cotter, Katherine, et al.
Publicado: (2016)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice
por: Gómez Rivas, Juan, et al.
Publicado: (2022)

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
por: Hoeh, Benedikt, et al.
Publicado: (2021)

Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients
por: Flammia, Rocco S., et al.
Publicado: (2022)

The percentage of high‐grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death
por: Berney, Daniel M, et al.
Publicado: (2019)

Retzius-sparing Robot-assisted Radical Prostatectomy in High-risk Prostate Cancer Patients: Results from a Large Single-institution Series
por: Dell'Oglio, Paolo, et al.
Publicado: (2022)

Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU Prostate Cancer Working Group multi-institutional study
por: Zattoni, Fabio, et al.
Publicado: (2021)

Contemporary seminal vesicle invasion rates in NCCN high‐risk prostate cancer patients
por: Flammia, Rocco S., et al.
Publicado: (2022)

Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions
por: Zattoni, Fabio, et al.
Publicado: (2023)

New prostate cancer grade group system correlates with prostate cancer death in addition to biochemical recurrence
por: Epstein, Jonathan I
Publicado: (2016)

Contemporary role of postoperative radiotherapy for prostate cancer
por: Dal Pra, Alan, et al.
Publicado: (2018)

Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target
por: Mistretta, Francesco, et al.
Publicado: (2014)

Pelvic nodal radiotherapy in Gleason grade group 5 prostate cancer
por: Cook, Kiri, et al.
Publicado: (2020)

Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review
por: Yang, Che-Hsueh, et al.
Publicado: (2022)

Local failure in high grade prostate cancer: the importance of local and systemic therapy
por: Kishan, Amar U., et al.
Publicado: (2020)

Impact of the COVID-19 Pandemic on Urologic Oncology Surgery: Implications for Moving Forward
por: Guerrieri, Rossella, et al.
Publicado: (2021)

Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer
por: Bravi, Carlo A., et al.
Publicado: (2022)

The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence
por: Bianchi, Lorenzo, et al.
Publicado: (2022)

PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment
por: Bianchi, Lorenzo, et al.
Publicado: (2023)

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol
por: Beyer, Katharina, et al.
Publicado: (2021)

Sense and Nonsense of an Extended Pelvic Lymph Node Dissection in Prostate Cancer
por: Van Baelen, Anthony, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_apdbh447upmoe0fo42gra70mee